As the only two - dose hepatitis B vaccine for adults that also sports
a superior efficacy profile to GlaxoSmithKline's Engerix - B, Dynavax should be able to easily gobble up the lion's share of this market moving forward.
It is a differentiated PPAR gamma agonist with a
superior profile for CNS related diseases with excellent in - vivo
efficacy, a comprehensive development plan and early involvement from key opinion leaders.